Putting the award page together from the records…
Putting the award page together from the records…
ADVANCED RESEARCH AND DEVELOPMENT AND DELIVERY OF ADULT AND PEDIATRIC MIDAZOLAM AUTOINJECTORS THAT HAVE RECEIVED EMERGENCY USE AUTHORIZATION (EUA) OR FDA APPROVAL FOR THE TREATMENT OF STATUS EPILEPTICUS SEIZURES IN ADULT AND PEDIATRIC POPULATIONS (2+
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
3 actions since 2024-05-31. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-09-23 | P00004 | Funding only | $4.69M | PROVIDE SUPPLEMENTAL FUNDING, EXTEND THE PERIOD OF PERFORMANCE FOR CLIN0001 AND UPDATE SECTION J LIST OF ATTACHMENTS ATTACHMENT 1 STATEMENT OF WORK |
| 2025-09-16 | P00003 | Funding only | $11.29M | SUPPLEMENTAL FUNDING FOR CLIN 001 AND REVISED THE STATEMENT OF WORK. |
| 2024-05-31 | P00002 | Administrative change | $0 | ADVANCED RESEARCH AND DEVELOPMENT AND DELIVERY OF ADULT AND PEDIATRIC MIDAZOLAM AUTOINJECTORS THAT HAVE RECEIVED EMERGENCY USE AUTHORIZATION (EUA) OR FDA APPROVAL FOR THE TREATMENT OF STATUS EPILEPTICUS SEIZURES IN ADULT AND PEDIATRIC POPULATIONS (2+ |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-20). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗